Tilray Medical, a division of Tilray Brands, Inc. (NASDAQ: TLRY, TSX: TLRY), announced the commercial launch of its first medical cannabis product in Panama on July 09, 2026. This strategic move marks a significant milestone in the company’s global expansion, aiming to improve patient access to pharmaceutical-grade cannabinoid medicines in Latin America. The launch involves Tilray Oral Solution CBD100, distributed through Farmacias Arrocha, one of Panama’s leading pharmacy networks.

The product shipment originated from Tilray Medical’s EU-GMP-certified production facilities in Portugal, conducted through a joint venture with Solana Life Group S. de R.L. Patients can access Tilray Oral Solution CBD 100 under medical prescription, providing regulated, pharmaceutical-quality medical cannabis through established healthcare channels. The launch aligns with Panama’s medical cannabis framework established under Law 242 of 2021 and follows Resolution No. 0406 of May 12, 2026, issued by the Ministry of Health.

Rajnish Ohri, President, International, Tilray Brands, stated that the launch reflects the company's vision to expand access to cannabinoid-based medicines through trusted healthcare systems. He emphasized the commitment to working alongside healthcare providers, regulators, and patients to advance medical education and deliver high-quality treatment options.

Tilray Medical serves patients across more than 20 countries, including Europe, Australia, Canada, and Latin America. The company’s facilities in Portugal serve as a strategic global export hub, supplying EU-GMP-certified medical cannabis products to regulated markets. The Panama launch represents another step in Tilray Medical’s broader strategy to expand access across Latin America, an emerging region for medical cannabis.

The Ministry of Health recently introduced the Medical Cannabis Users and Authorized Caregivers Identification System (SIUCMAA), creating a structured pathway for physician authorization and patient registration. Tilray Oral Solution CBD100 is intended for use in patients with qualifying medical conditions authorized under Panamanian legislation, adhering to rigorous European Union Good Manufacturing Practice (EU-GMP) standards.

Key Details of the Launch

Tilray Medical remains focused on advancing patient care, supporting clinical education, and investing in research to address unmet patient needs worldwide. The company continues to leverage its platform to support growing international demand while maintaining high pharmaceutical manufacturing standards.

Tilray Brands, Inc. has acquired HelloMD Corporation to strengthen its global medical cannabis platform and establish a fully vertically integrated framework in Canada. The acquisition, announced on June 29, 2026, follows Tilray's successful bid in HelloMD’s formal sale process. The transaction is subject to formal Court approval on June 29, 2026. Financial terms of the deal were not disclosed.

The acquisition expands Tilray’s direct-to-patient capabilities by integrating HelloMD’s digital healthcare platform, which offers telehealth consultations, educational resources, and personalized medical cannabis guidance. This move connects Tilray’s cultivation, clinical expertise, and fulfillment infrastructure with patient engagement tools. The company aims to engage patients earlier in their care journey through education and practitioner access.

Strategic Integration

The combination creates a connected pathway for patients and healthcare practitioners in Canada. HelloMD has supported hundreds of thousands of patients through its platform. The integration complements Tilray’s existing global healthcare infrastructure, which includes EU-GMP certified cultivation, pharmaceutical distribution via CC Pharma, and medical clinics across North America, Europe, Australia, and other international markets.

Management Commentary

Blair MacNeil, President, Tilray Canada, stated that the acquisition establishes a fully vertically integrated medical cannabis framework for Tilray in Canada. He emphasized that the combination of HelloMD’s digital platform with Tilray’s portfolio and fulfillment capabilities creates a more connected pathway for patients and practitioners.

Larry Lisser, CEO, HelloMD, noted that Tilray has the expertise and infrastructure to expand the platform’s reach. He expressed confidence that the acquisition will benefit patients by scaling the delivery of meaningful outcomes.

Future Expansion

Tilray intends to use HelloMD’s digital education and engagement capabilities to broaden awareness in adjacent wellness categories, such as sleep support and pain management. The company aims to responsibly build awareness of regulated, plant-based medical cannabis alternatives among audiences seeking natural health solutions, subject to applicable regulations.